Renewed interest in a difficult disease: Clostridium difficile infections - epidemiology and current treatment strategies

被引:63
作者
McFarland, Lynne V. [1 ]
机构
[1] Puget Sound VA HealthCare Syst, Dept Hlth Serv Res & Dev, Seattle, WA 98101 USA
关键词
BI/NAP1/027; strain; Clostridium difficile; epidemiology; outbreaks; ANTIBIOTIC-ASSOCIATED DIARRHEA; PLACEBO-CONTROLLED TRIAL; TERM-CARE FACILITY; REAL-TIME PCR; TOXIN-A; HEALTH-CARE; HOSPITALIZED-PATIENTS; FUSIDIC ACID; DOUBLE-BLIND; SACCHAROMYCES-BOULARDII;
D O I
10.1097/MOG.0b013e32831da7c4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose of review Renewed interest in Clostridium difficile infections (CDI) is stimulating research into the pathogenesis and virulence factors for this pathogen. This review summarizes recent progress in the field, particularly in relation to the changing apidemiologis trends and new investigational treatments. Recent findings Elucidation of the role of different toxins of C. difficile (tcdA, tcdB and binary toxin) is deepening our understanding of CDI. Stain typing of C. difficile isolates is documenting the spread of an emergent strain (BI/NAP1/027) associated with large outbreaks of severe disease. Typing of isolates around the world shows global spread of this strain. Reliance upon metronidazole is questioned due to a lower response rate and newer investigational therapies are reported. Summary After being considered a manageable pathogen for decades, C. difficile recently caused large outbreaks of severe disease. Refocused research is determining patients who are at risk for CDI, what methods are more effective in diagnosing CDI and what new treatments may be effective. This article reviews the recent findings in the literature regarding this difficult and challenging pathogen.
引用
收藏
页码:24 / 35
页数:12
相关论文
共 93 条
[1]   Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube [J].
Aas, J ;
Gessert, CE ;
Bakken, JS .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :580-585
[2]   Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin [J].
Al-Nassir, Wafa N. ;
Sethi, Ajay K. ;
Nerandzic, Michelle M. ;
Bobulsky, Greg S. ;
Jump, Robin L. P. ;
Donskey, Curtis J. .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (01) :56-62
[3]   Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis:: Case series and review of the literature [J].
Apisarnthanarak, A ;
Razavi, B ;
Mundy, LM .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (06) :690-696
[4]   A European survey of diagnostic methods and testing protocols for Clostridium difficile [J].
Barbut, F ;
Delmée, M ;
Brazier, JS ;
Petit, JC ;
Poxton, IR ;
Rupnik, M ;
Lalande, V ;
Schneider, C ;
Mastrantonio, P ;
Alonso, R ;
Kuipjer, E ;
Tvede, M .
CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (10) :989-996
[5]   Clinical features of Clostridium difficile-associated infections and molecular characterization of strains:: Results of a retrospective study, 2000-2004 [J].
Barbut, Frederic ;
Gariazzo, Beatrice ;
Bonne, Laetitia ;
Lalande, Valerie ;
Burghoffer, Beatrice ;
Luiuz, Ralucca ;
Petit, Jean-Claude .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (02) :131-139
[6]   The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection [J].
Bartlett, John G. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (10) :1489-1492
[7]  
Bauer MP, 2008, NETH J MED, V66, P207
[8]   Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit [J].
Beaulieu, Mathieu ;
Williamson, David ;
Pichette, Gilbert ;
Lachaine, Jean .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (11) :1305-1307
[9]   National Clostridium difficile standards group:: Report to the department of health [J].
Berrington, A ;
Borriello, SP ;
Brazier, J ;
Duckworth, G ;
Foster, K ;
Freeman, R ;
Gould, FK ;
Henderson, J ;
Hollyoak, V ;
Spencer, R ;
Taylor, J ;
Wilcox, M .
JOURNAL OF HOSPITAL INFECTION, 2004, 56 :1-38
[10]   Moxifloxacin therapy as a risk factor for clostridium difficile-associated disease during an outbreak: Attempts to control a new epidemic strain [J].
Biller, Priscilla ;
Shank, Beth ;
Lind, Leah ;
Brennan, Meghan ;
Tkatch, Lisa ;
Killgore, George ;
Thompson, Angela ;
McDonald, L. Clifford .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (02) :198-201